Feed - News and features https://pharmaphorum.com/ en Thu, 06 Feb 2025 16:58:39 +0000 Thu, 06 Feb 2025 13:22:02 +0000 BMS extends its cost-cutting drive by another $2bn https://pharmaphorum.com/news/bms-extends-its-cost-cutting-drive-another-2bn BMS is extending its bid to cut costs by $1.5bn before the end of this year, backed by 2200 job cuts, adding a target of another $2bn by end-2027. Phil.Taylor https://pharmaphorum.com/news/bms-extends-its-cost-cutting-drive-another-2bn 2025-02-06T13:22:02+0000 Feed - News and features Pressure relieved on AZ as details of Chinese probe emerge https://pharmaphorum.com/news/pressure-relieved-az-details-chinese-probe-emerge AstraZeneca's exposure to liability in a Chinese investigation into illegal drug imports appears to be much less than had been feared. Phil.Taylor https://pharmaphorum.com/news/pressure-relieved-az-details-chinese-probe-emerge 2025-02-06T12:15:17+0000 Feed - News and features Newel's VR therapy for chronic pain nears EU market https://pharmaphorum.com/news/newels-vr-therapy-chronic-pain-nears-eu-market Newel Health has been granted EU certification for its VR-based digital therapeutic for chronic pain, clearing the way for its launch in Europe. Phil.Taylor https://pharmaphorum.com/news/newels-vr-therapy-chronic-pain-nears-eu-market 2025-02-06T11:19:07+0000 Feed - News and features Pharma group slams Hims & Hers over Super Bowl GLP-1 ad https://pharmaphorum.com/news/pharma-group-slams-hims-hers-over-super-bowl-glp-1-ad Partnership for Safe Medicines claims the Hims & Hers ad for compounded weight-loss drug semaglutide, due to run during the Super Bowl, is "reckless." Phil.Taylor https://pharmaphorum.com/news/pharma-group-slams-hims-hers-over-super-bowl-glp-1-ad 2025-02-06T10:27:19+0000 Feed - News and features Novo charts course ahead for CagriSema after lacklustre data https://pharmaphorum.com/news/novo-charts-course-ahead-cagrisema-after-lacklustre-data After its first phase 3 trial of obesity hope CagriSema left investors dissatisfied, Novo Nordisk has a plan to get the programme back on track. Phil.Taylor https://pharmaphorum.com/news/novo-charts-course-ahead-cagrisema-after-lacklustre-data 2025-02-06T09:36:48+0000 Feed - News and features